Massmedica (WAR:MSM) Beneish M-Score: -0.46 (As of Jul. 17, 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

WAR:MSM Massmedica SA WAR:MSM
84 GF Score
Price zł4.50
GF Value zł4.31
Valuation Fairly Valued
! 4 Warning Signs
View Full Analysis

What is Massmedica Beneish M-Score?

Massmedica WAR:MSM +2.27% 84 Beneish M-Score is -0.46 as of Jul. 17, 2026. GuruFocus rates WAR:MSM with a GF Score™ of 84/100 and a GF Value™ of zł4.31 (Fairly Valued). The stock has 4 warning signs investors should review. Among 763 Medical Devices & Instruments companies, Massmedica ranks worse than 92.27% on this metric.

The zones of discrimination for M-Score is as such:

An M-Score of equal or less than -1.78 suggests that the company is unlikely to be a manipulator.
An M-Score of greater than -1.78 signals that the company is likely to be a manipulator.

Warning Sign:

Beneish M-Score -0.46 higher than -1.78, which implies that the company might have manipulated its financial results.

The historical rank and industry rank for Massmedica's Beneish M-Score or its related term are showing as below:

WAR:MSM' s Beneish M-Score Range Over the Past 10 Years
Min: -3.5   Med: -2.1   Max: 784.9
Current: -0.46

During the past 10 years, the highest Beneish M-Score of Massmedica was 784.90. The lowest was -3.50. And the median was -2.10.


Massmedica Beneish M-Score Historical Data

* Premium members only.

The historical data trend for Massmedica's Beneish M-Score can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Massmedica Beneish M-Score Chart

Massmedica Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Beneish M-Score
Get a 7-Day Free Trial Premium Member Only Premium Member Only -2.01 -2.19 -2.10 -3.50 -0.46

Massmedica Quarterly Data
Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26
Beneish M-Score Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.00 0.00 0.00 -0.46 0.00

WAR:MSM vs ABT, SYK, MDT: Beneish M-Score Comparison

For the Medical Devices subindustry, Massmedica's Beneish M-Score, along with its competitors' market caps and Beneish M-Score data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Massmedica Beneish M-Score vs Medical Devices & Instruments Industry

For the Medical Devices & Instruments industry and Healthcare sector, Massmedica's Beneish M-Score distribution charts can be found below:

* The bar in red indicates where Massmedica's Beneish M-Score falls into.


WAR:MSM
84GF Score
Massmedica SA WAR:MSM
Beneish M-Score is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Massmedica Beneish M-Score Calculation

The M-score was created by Professor Messod Beneish. Instead of measuring the bankruptcy risk (Altman Z-Score) or business trend (Piotroski F-Score), M-score can be used to detect the risk of earnings manipulation. This is the original research paper on M-score.

The M-Score Variables:

The M-score of Massmedica for today is based on a combination of the following eight different indices:

M=-4.84+0.92 * DSRI+0.528 * GMI+0.404 * AQI+0.892 * SGI+0.115 * DEPI
=-4.84+0.92 * 2.6689+0.528 * 1.0258+0.404 * 1.1038+0.892 * 0.988+0.115 * 1.0181
-0.172 * SGAI+4.679 * TATA-0.327 * LVGI
-0.172 * 1+4.679 * 0.098133-0.327 * 1.0561
=-0.46

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

This Year (Dec25) TTM:Last Year (Dec24) TTM:
Total Receivables was zł8.26 Mil.
Revenue was zł32.22 Mil.
Gross Profit was zł12.83 Mil.
Total Current Assets was zł22.37 Mil.
Total Assets was zł25.01 Mil.
Property, Plant and Equipment(Net PPE) was zł2.59 Mil.
Depreciation, Depletion and Amortization(DDA) was zł0.48 Mil.
Selling, General, & Admin. Expense(SGA) was zł0.00 Mil.
Total Current Liabilities was zł17.25 Mil.
Long-Term Debt & Capital Lease Obligation was zł0.00 Mil.
Net Income was zł0.54 Mil.
Gross Profit was zł0.00 Mil.
Cash Flow from Operations was zł-1.92 Mil.
Total Receivables was zł3.13 Mil.
Revenue was zł32.61 Mil.
Gross Profit was zł13.32 Mil.
Total Current Assets was zł17.49 Mil.
Total Assets was zł20.36 Mil.
Property, Plant and Equipment(Net PPE) was zł2.85 Mil.
Depreciation, Depletion and Amortization(DDA) was zł0.54 Mil.
Selling, General, & Admin. Expense(SGA) was zł0.00 Mil.
Total Current Liabilities was zł13.30 Mil.
Long-Term Debt & Capital Lease Obligation was zł0.00 Mil.




1. DSRI = Days Sales in Receivables Index

Measured as the ratio of Revenue in Total Receivables in year t to year t-1.

A large increase in DSR could be indicative of revenue inflation.

DSRI=(Receivables_t / Revenue_t) / (Receivables_t-1 / Revenue_t-1)
=(8.259 / 32.221) / (3.132 / 32.611)
=0.256324 / 0.096041
=2.6689

2. GMI = Gross Margin Index

Measured as the ratio of gross margin in year t-1 to gross margin in year t.

Gross margin has deteriorated when this index is above 1. A firm with poorer prospects is more likely to manipulate earnings.

GMI=GrossMargin_t-1 / GrossMargin_t
=(GrossProfit_t-1 / Revenue_t-1) / (GrossProfit_t / Revenue_t)
=(13.324 / 32.611) / (12.834 / 32.221)
=0.408574 / 0.398312
=1.0258

3. AQI = Asset Quality Index

AQI is the ratio of asset quality in year t to year t-1.

Asset quality is measured as the ratio of non-current assets other than Property, Plant and Equipment to Total Assets.

AQI=(1 - (CurrentAssets_t + PPE_t) / TotalAssets_t) / (1 - (CurrentAssets_t-1 + PPE_t-1) / TotalAssets_t-1)
=(1 - (22.372 + 2.593) / 25.007) / (1 - (17.488 + 2.845) / 20.364)
=0.00168 / 0.001522
=1.1038

4. SGI = Sales Growth Index

Ratio of Revenue in year t to sales in year t-1.

Sales growth is not itself a measure of manipulation. However, growth companies are likely to find themselves under pressure to manipulate in order to keep up appearances.

SGI=Sales_t / Sales_t-1
=Revenue_t / Revenue_t-1
=32.221 / 32.611
=0.988

5. DEPI = Depreciation Index

Measured as the ratio of the rate of Depreciation, Depletion and Amortization in year t-1 to the corresponding rate in year t.

DEPI greater than 1 indicates that assets are being depreciated at a slower rate. This suggests that the firm might be revising useful asset life assumptions upwards, or adopting a new method that is income friendly.

DEPI=(Depreciation_t-1 / (Depreciaton_t-1 + PPE_t-1)) / (Depreciation_t / (Depreciaton_t + PPE_t))
=(0.538 / (0.538 + 2.845)) / (0.48 / (0.48 + 2.593))
=0.15903 / 0.156199
=1.0181

Note: If the Depreciation, Depletion and Amortization data is not available, we assume that the depreciation rate is constant and set the Depreciation Index to 1.

6. SGAI = Sales, General and Administrative expenses Index

The ratio of Selling, General, & Admin. Expense(SGA) to Sales in year t relative to year t-1.

SGA expenses index > 1 means that the company is becoming less efficient in generate sales.

SGAI=(SGA_t / Sales_t) / (SGA_t-1 /Sales_t-1)
=(0 / 32.221) / (0 / 32.611)
=0 / 0
=1

7. LVGI = Leverage Index

The ratio of total debt to Total Assets in year t relative to yeat t-1.

An LVGI > 1 indicates an increase in leverage

LVGI=((LTD_t + CurrentLiabilities_t) / TotalAssets_t) / ((LTD_t-1 + CurrentLiabilities_t-1) / TotalAssets_t-1)
=((0 + 17.246) / 25.007) / ((0 + 13.298) / 20.364)
=0.689647 / 0.653015
=1.0561

8. TATA = Total Accruals to Total Assets

Total accruals calculated as the change in working capital accounts other than cash less depreciation.

TATA=(IncomefromContinuingOperations_t - CashFlowsfromOperations_t) / TotalAssets_t
=(NetIncome_t - NonOperatingIncome_t - CashFlowsfromOperations_t) / TotalAssets_t
=(0.536 - 0 - -1.918) / 25.007
=0.098133

An M-Score of equal or less than -1.78 suggests that the company is unlikely to be a manipulator. An M-Score of greater than -1.78 signals that the company is likely to be a manipulator.

Massmedica has a M-score of -0.46 signals that the company is likely to be a manipulator.

Frequently Asked Questions Learn more about Beneish M-Score →
What does a Beneish M-Score of -0.46 mean?
Massmedica (WAR:MSM) has a Beneish M-Score of -0.46 as of Jul. 17, 2026. The Beneish M-score measures the likelihood of earnings manipulation. View historical data on Massmedica and its competitors. According to the industry distribution chart, Massmedica ranks #704 out of 763 companies in the Medical Devices & Instruments industry, placing it in the top 92.3%.
Is Massmedica's Beneish M-Score too high?
Massmedica's current Beneish M-Score is -0.46. Based on the distribution chart, Massmedica ranks #704 out of 763 companies in the Medical Devices & Instruments industry, which is in the bottom quartile relative to peers. Overall, Massmedica has a GF Score™ of 84/100 and is considered Fairly Valued, reflecting its overall financial health beyond just this single metric.
How does Massmedica's Beneish M-Score compare to ABT and SYK?
According to the Medical Devices & Instruments industry distribution chart, Massmedica ranks #704 out of 763 companies for Beneish M-Score. This places Massmedica in the lower half of its industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Beneish M-Score for a Medical Devices & Instruments company?
A good Beneish M-Score depends on the Medical Devices & Instruments industry context. However, Beneish M-Score should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Beneish M-Score mean?
A high Beneish M-Score can signal that a stock is expensive relative to its fundamentals. The Beneish M-score measures the likelihood of earnings manipulation. View historical data on Massmedica and its competitors. Massmedica's current Beneish M-Score is -0.46. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Massmedica stock overvalued right now?
Based on GuruFocus' analysis, Massmedica (WAR:MSM) is currently considered Fairly Valued. The stock's GF Value™ is zł4.31, compared to a current price of zł4.50 — trading 4.4% above its estimated fair value. The current Beneish M-Score is -0.46. Massmedica's overall GF Score™ is 84/100 with 4 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Beneish M-Score calculated?
Beneish M-Score is calculated from a company's financial statements. For Massmedica (WAR:MSM), the current Beneish M-Score is -0.46 as of Jul. 17, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Massmedica (WAR:MSM) Overvalued in 2026?

Based on GuruFocus' analysis, Massmedica stock appears to be overvalued. The current stock price of zł4.50 is trading 4.4% above its estimated GF Value™ of zł4.31. GuruFocus considers Massmedica to be Fairly Valued.

Key valuation signals for WAR:MSM:

  • Beneish M-Score: -0.46
  • GF Value™: zł4.31 vs. price of zł4.50 (4.4% above fair value)
  • GF Score™: 84/100 with 4 warning signs

No single metric tells the full story. See the WAR:MSM stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.


Massmedica Business Description

Address ul. Adama Branickiego 17, Wilanow, Warsaw, POL, 02-972
Massmedica SA is operating in the areas of reconstructive, regenerative, anti-aging and aesthetic medicine. It deals in the distribution of implants and other medical materials used in the treatment of diseases of the musculoskeletal system and in regenerative medicine.
84GF Score

Get the complete analysis for WAR:MSM

Beneish M-Score is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

zł4.50
Price
zł4.31
GF Value